This study aimed to examine the effects of nitric oxide (NO) and different phosphodiesterase (PDE) families on meiosis resumption, nucleotides levels and embryo production. Experiment I, COCs were matured in vitro with the NO donor S-nitroso-N-acetylpenicillamine (SNAP) associated or not with the soluble guanylate cyclase (sGC) inhibitor 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ), meiotic resumption and nucleotides levels were assessed. SNAP delayed germinal vesicle breakdown (GVBD) (53.4 ± 1.2 versus 78.4 ± 2.4% for controls, P < 0.05) and ODQ reversed its effect (73.4 ± 6.3%, P > 0.05). Cyclic GMP levels were higher in SNAP (3.94 ± 0.18, P < 0.05) and ODQ abolished the effect (2.48 ± 0.13 pmol/COC, P < 0.05), while cAMP levels were decreased in both treatments. Experiment II, COCs were cultured with SNAP alone or with PDEs inhibitors. SNAP alone or with PDEs inhibitors delayed GVBD (24.7 ± 2.8 to 56.9 ± 8.7%, P < 0.05) compared with the control (77.1 ± 1.8%), and SNAP and SNAP + cilostamide had lowest rates (34.9 ± 9.2% and 24.7 ± 2.8%). Experiment III, COCs were cultured (24–28 h) with SNAP and SNAP + cilostamide to assess metaphase II (MII) rates and embryo production. SNAP + cilostamide (50.0 ± 2.0%, P < 0.05) had lower MII rates at 24 h in vitro maturation (IVM), but at 28 h all groups were similar (66.6 to 71.4%, P > 0.05). Embryo development did not differ from the control for SNAP and cilostamide groups (38.7 ± 5.8, 37.9 ± 6.2 and 40.5 ± 5.8%, P > 0.05), but SNAP + cilostamide decreased embryo production (25.7 ± 6.9%, P < 0.05). In conclusion, SNAP was confirmed to delay meiosis resumption by the NO/sGC/cGMP pathway, by increasing cGMP, but not cAMP. Inhibiting different PDEs to further increase nucleotides in association with SNAP did not show any additive effects on meiosis resumption, indicating that other pathways are involved. Moreover, SNAP + cilostamide affected the meiosis progression and decreased embryo development.

Biotin is a member of the vitamin B-complex family. Biotin deficiency has been associated with hyperglycaemia and insulin resistance in animals and humans. In the present study, we investigated the pharmacological effects of biotin on hypertension in the stroke-prone spontaneously hypertensive rat (SHRSP) strain. We observed that long-term administration of biotin decreased systolic blood pressure in the SHRSP strain; also, a single dose of biotin immediately decreased systolic blood pressure in this strain. Pretreatment with the guanylate cyclase inhibitor 1H-[1,2,4]oxadiazole [4,3-α]quinoxalin-1-one abolished the hypotensive action of biotin in the SHRSP strain, while pretreatment with the NO synthase inhibitor NG-nitro-l-arginine methyl ester had no effect on the action of biotin. Biotin reduced coronary arterial thickening and the incidence of stroke in the SHRSP strain. These results suggest that the pharmacological dose of biotin decreased the blood pressure of the SHRSP via an NO-independent direct activation of soluble guanylate cyclase. Our findings reveal the beneficial effects of biotin on hypertension and the incidence of stroke.

The second messenger cyclic guanosine monophosphate (cGMP) plays a role in many aspects of retinal processing. cGMP-gated channels function in photoreceptors, Müller, bipolar, and ganglion cells; and cGMP can modulate gap-junction conductivity. In the inner retina, both particulate and soluble guanylate cyclases can elevate levels of cGMP. The soluble isoform of guanylate cyclase is activated by nitric oxide (NO). In turtle retina, nitric oxide synthase, the enzyme that synthesizes NO, has been previously localized in discrete amacrine cells, somata in the ganglion cell layer, and in many processes in the inner plexiform layer. However, there have been no studies localizing soluble guanylate cyclase in the turtle retina. To functionally localize soluble guanylate cyclase, we stimulated retinas with the NO donors (±)-S-nitroso-N-acetylpenicillamine or spermine (nitric oxide) adduct, and then used immunocytochemistry to localize increases in cGMP-like immunoreactivity (cGMP-LI). The cells containing soluble guanylate cyclase should show cell autonomous increases in cGMP-LI in response to stimulation with NO. NO-stimulated increases in cGMP-LI occurred in many distinct amacrine cell types, select bipolar cells, some somata in the ganglion cell layer, and in discrete bands of processes in the inner plexiform layer. The pattern of cGMP-LI demonstrated qualitative dose response differences to the NO donors. This is the first localization of soluble guanylate cyclase in specific retinal neurons in the turtle; and the first functional activation of soluble guanylate cyclase in the amacrine cells of any species. The broad neuronal distribution of NO-stimulated cGMP-LI suggests that the NO/soluble guanylate cyclase/cGMP cascade is involved at several levels of visual processing in the inner retina.